EVOK - Evoke Pharma Inc. Operating income before deduction of amortization

Public company logo of Evoke Pharma (EVOK)

Evoke Pharma, Inc. (EVOK) is optimizing costs by outsourcing the international logistics of its nasal products to third-party operators. However, the stability of raw material supplies from Asia and geopolitical tensions create risks of product shortages. Partnerships with distributors are expanding patient access to gastrointestinal therapies. The current EBITDA_Co level reflects pre-tax profit dynamics, where 0.00 describes the current status of the metric.

Evoke Pharma - EVOK Operating profit EBITDA (period 11/23/2025 - 12/27/2025)

Summary analytical data breakdowns for Evoke Pharma (EVOK)

- price and consensus price forecast:
Price Rate Chart Evoke Pharma Inc|EVOK - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Evoke Pharma|EVOK - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Price of a Share Evoke Pharma|EVOK - Book Capitalization|Market-to-Book Ratio evokepharma.com|EVOK - Cumulative Company Assets
- company total debt and liquidity indicators:
Debt to Equity Evoke Pharma, Inc.|EVOK - Long-Term Debt to Equity|Current Liabilities to Capital Evoke Pharma Inc.|EVOK - Company Debts|Debts to Book Capitalization Evoke Pharma|EVOK - Company Long-Term Debts|Short-Term Debt Evoke Pharma|Intermediate Coverage Ratio evokepharma.com
- financial results and valuation multiples details:
EVOK - Company Net Income|Forward Earnings Evoke Pharma, Inc.|EVOK - P/E Multiple|Future Price to Earnings Multiple evokepharma.com|EVOK - PEG Multiple|EV/EBITDA Multiple Evoke Pharma|EVOK - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Evoke Pharma|EVOK - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months evokepharma.com|EVOK - Earnings growth in current year|Earnings growth forecast for next year Evoke Pharma, Inc.
- sales revenue and business income indicators:
EVOK - Company Sales|Company Future Revenue Evoke Pharma Inc|EVOK - P/S Multiple|Market Cap to Expected Sales Ratio Evoke Pharma
Analysis of all company metrics:EVOK (Evoke Pharma Inc)
Manufactured products of Evoke Pharma, Inc.

This indicator measures the amount of cash generated by the core business before depreciation and interest, allowing for an assessment of the real liquidity generation potential excluding accounting write-offs. By analyzing the cash EBITDA, an investor determines the commercialization efficiency of the drug Gimoti, assessing the extent to which nasal spray sales can ensure the operational stability of Evoke Pharma, Inc. (EVOK) during the product's maturity stage.

Who Evoke Pharma, Inc. competes with

Operating profit before depreciation charges Phathom|Terns Pharmaceuticals - Operating profit EBITDA|Operating income before deduction of amortization Ironwood Pharmaceuticals IRWD|CURX (curanexpharma.com) - Operating profit before deduction of amortization|IMRN: Company profit before taxes, interest and amortization|ENTO (Entero Therapeutics Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization RedHill RDHL|Operating profit before deduction of amortization PALI (Palisade Bio)|Profit before payment of interest, taxes and amortization JAGX (jaguar.health)|Profit before payment of interest, taxes and amortization Biora Therapeutics, Inc. BIOR|Morphic Therapeutic (MORF) - Profit before interest, taxes and amortization